Market Newsdesk

GETTYSBURG, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) — ACNB Corporation was recently recognized, with a ranking of #45, by the Central Penn Business Journal on its annual list of the Fastest Growing Companies in Central Pennsylvania for 2023. This is the sixth consecutive year ACNB Corporation has achieved this recognition.

“The 2023 Fastest Growing Companies have excelled during challenging economic times. These businesses are creative, innovative and know how to overcome hurdles,” said Suzanne Fischer-Huettner, managing director of Central Penn Business Journal/BridgeTower Media. “All of us at the Central Penn Business Journal congratulate this year’s honorees.”

James P. Helt, ACNB Corporation President & Chief Executive Officer, stated, “At ACNB Corporation, the financial holding company for ACNB Bank and ACNB Insurance Services, Inc., our fundamental focus remains to be the independent financial services provider of choice in the communities served throughout our geographic footprint in southcentral Pennsylvania and central Maryland by building relationships and finding solutions. Despite the unusual and unprecedented economic times over the past few years, our organizational longevity — that spans 166 years — is directly attributable to the generations of dedicated staff members that fulfilled, and continue to fulfill, our commitment to customers, shareholders and communities served.”

“Specific to this Fastest Growing Companies recognition is revenue growth, which is a result of ACNB Corporation’s community bank acquisitions in recent years in alignment with our plans for strategic inorganic growth in tandem with ongoing organic growth,” he added. “As for the year 2022, ACNB Corporation completed key strategic initiatives including the acquisition by the insurance subsidiary, ACNB Insurance Services, Inc., of the business and assets of Hockley & O’Donnell Insurance Agency in Gettysburg, PA, and the opening of the new Upper Adams Office in Biglerville, PA, as the banking subsidiary, ACNB Bank, continued its plans for optimization of the community banking network. As in the past five years, ACNB Corporation is truly honored to be recognized for our achievements and is poised for continued progress and growth in the years to come.”

In order to be eligible for consideration in this ranking for 2023, companies were required to show revenue of at least $500,000 in each of the fiscal years ending 2020, 2021 and 2022, as well as revenue growth in 2022, as compared to 2020. Companies headquartered in the Pennsylvania counties of Adams, Cumberland, Dauphin, Franklin, Lancaster, Lebanon, Perry or York were eligible for nomination.

SEK CPAs & Advisors coordinated the ranking formula leading to the recognition of large and small companies according to revenue growth over the three-year period. Including both dollar and percentage revenue increases, this ranking formula resulted in the final list of 50 honorees recognized at a celebration event held at the Sheraton Harrisburg Hershey Hotel, 4650 Lindle Road, Harrisburg, PA, on Tuesday, September 12, 2023, when specific rankings were revealed.

ACNB Corporation, headquartered in Gettysburg, PA, is the independent $2.4 billion financial holding company for the wholly-owned subsidiaries of ACNB Bank, Gettysburg, PA, and ACNB Insurance Services, Inc., Westminster, MD. Originally founded in 1857, ACNB Bank serves its marketplace with banking and wealth management services, including trust and retail brokerage, via a network of 26 community banking offices and three loan offices located in the Pennsylvania counties of Adams, Cumberland, Franklin, Lancaster and York and the Maryland counties of Baltimore, Carroll and Frederick. ACNB Insurance Services, Inc. is a full-service insurance agency with licenses in 44 states. The agency offers a broad range of property, casualty, health, life and disability insurance serving personal and commercial clients through office locations in Westminster and Jarrettsville, MD, and Gettysburg, PA. For more information regarding ACNB Corporation and its subsidiaries, please visit investor.acnb.com.

Fastest Growing Companies is a program of the Central Penn Business Journal and is presented by SEK CPAs & Advisors. For more information about the awards and honorees, please visit CPBJ.com/event/fastest-growing-companies.

FORWARD-LOOKING STATEMENTS – In addition to historical information, this press release may contain forward-looking statements. Examples of forward-looking statements include, but are not limited to, (a) projections or statements regarding future earnings, expenses, net interest income, other income, earnings or loss per share, asset mix and quality, growth prospects, capital structure, and other financial terms, (b) statements of plans and objectives of Management or the Board of Directors, and (c) statements of assumptions, such as economic conditions in the Corporation’s market areas. Such forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “intends”, “will”, “should”, “anticipates”, or the negative of any of the foregoing or other variations thereon or comparable terminology, or by discussion of strategy. Forward-looking statements are subject to certain risks and uncertainties such as national, regional and local economic conditions, competitive factors, and regulatory limitations. Actual results may differ materially from those projected in the forward-looking statements. Such risks, uncertainties, and other factors that could cause actual results and experience to differ from those projected include, but are not limited to, the following: short-term and long-term effects of inflation and rising costs on the Corporation, customers and economy; effects of governmental and fiscal policies, as well as legislative and regulatory changes; effects of new laws and regulations (including laws and regulations concerning taxes, banking, securities and insurance) and their application with which the Corporation and its subsidiaries must comply; impacts of the capital and liquidity requirements of the Basel III standards; effects of changes in accounting policies and practices, as may be adopted by the regulatory agencies, as well as the Financial Accounting Standards Board and other accounting standard setters; ineffectiveness of the business strategy due to changes in current or future market conditions; future actions or inactions of the United States government, including the effects of short-term and long-term federal budget and tax negotiations and a failure to increase the government debt limit or a prolonged shutdown of the federal government; effects of economic conditions particularly with regard to the negative impact of any pandemic, epidemic or health-related crisis and the responses thereto on the operations of the Corporation and current customers, specifically the effect of the economy on loan customers’ ability to repay loans; effects of competition, and of changes in laws and regulations on competition, including industry consolidation and development of competing financial products and services; inflation, securities market and monetary fluctuations; risks of changes in interest rates on the level and composition of deposits, loan demand, and the values of loan collateral, securities, and interest rate protection agreements, as well as interest rate risks; difficulties in acquisitions and integrating and operating acquired business operations, including information technology difficulties; challenges in establishing and maintaining operations in new markets; effects of technology changes; effects of general economic conditions and more specifically in the Corporation’s market areas; failure of assumptions underlying the establishment of reserves for loan losses and estimations of values of collateral and various financial assets and liabilities; acts of war or terrorism or geopolitical instability; disruption of credit and equity markets; ability to manage current levels of impaired assets; loss of certain key officers; ability to maintain the value and image of the Corporation’s brand and protect the Corporation’s intellectual property rights; continued relationships with major customers; and, potential impacts to the Corporation from continually evolving cybersecurity and other technological risks and attacks, including additional costs, reputational damage, regulatory penalties, and financial losses. We caution readers not to place undue reliance on these forward-looking statements. They only reflect Management’s analysis as of this date. The Corporation does not revise or update these forward-looking statements to reflect events or changed circumstances. Please carefully review the risk factors described in other documents the Corporation files from time to time with the SEC, including the Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Please also carefully review any Current Reports on Form 8-K filed by the Corporation with the SEC.

ACNB #2023-17
September 13, 2023

WILLIAMSPORT, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) — Penns Woods Bancorp, Inc., (NASDAQ: PWOD) (the “Company”) announced today that it has filed with the Securities and Exchange Commission (SEC) a prospectus supplement to its existing shelf registration statement on Form S-3, under which it may offer and sell shares of its common stock having an aggregate offering price of up to $20 million from time to time through an “at-the-market” (ATM) equity offering program. The timing and amount of any sales will be determined by a variety of factors considered by the Company.

The shares will be offered through D.A. Davidson & Co., as sales agent. The sales agent may sell shares by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including without limitation, sales made directly on Nasdaq, on any other existing trading market for the shares, to or through a market maker or in negotiated transactions. Sales may be made at market prices prevailing at the time of the sale, at prices related to prevailing market prices or at negotiated prices and, as a result, sales prices may vary.

The prospectus supplement filed today adds to, updates or otherwise changes information contained in the existing prospectus contained in the Company’s shelf registration statement on Form S-3, which was declared effective by the SEC on July 18, 2023 (File No. 333-273018), for the offering of the securities covered by the registration statement. Prospective investors should read the prospectus, the prospectus supplement and other documents the Company has filed or submitted with the SEC (some of which are incorporated by reference into the prospectus and prospectus supplement) for more complete information about the Company and the ATM program, including the risks associated with investing in the Company. Investors may obtain copies of the prospectus supplement and accompanying prospectus relating to the offering without charge by visiting the SEC’s website at www.sec.gov. Alternatively, potential investors may contact Brian L. Knepp, the Company’s President and Chief Financial Officer, who will arrange to provide them with these documents, by telephone at (570) 320 – 2030 or by email at [email protected].

This press release is for informational purposes only and is not an offer to sell or the solicitation of an offer to buy any shares of the Company, which is made only by means of a prospectus supplement and related prospectus. There will be no sale of shares in any jurisdiction in which the offer, solicitation of an offer to buy or sale would be unlawful.

Penns Woods Bancorp, Inc. is the parent company of Jersey Shore State Bank, which operates sixteen branch offices providing financial services in Lycoming, Clinton, Centre, Montour, Union, and Blair Counties, and Luzerne Bank, which operates eight branch offices providing financial services in Luzerne County, and United Insurance Solutions, LLC, which offers insurance products. Investment and insurance products are offered through Jersey Shore State Bank’s subsidiary, The M Group, Inc. D/B/A The Comprehensive Financial Group.

This press release may contain certain “forward-looking statements” including statements concerning plans, objectives, future events or performance and assumptions and other statements, which are statements other than statements of historical fact. The Company cautions readers that the following important factors, among others, may have affected and could in the future affect actual results and could cause actual results for subsequent periods to differ materially from those expressed in any forward-looking statement made by or on behalf of the Company herein: (i) the effect of changes in laws and regulations, including federal and state banking laws and regulations, and the associated costs of compliance with such laws and regulations either currently or in the future as applicable; (ii) the effect of changes in accounting policies and practices, as may be adopted by the regulatory agencies as well as by the Financial Accounting Standards Board, or of changes in the Company’s organization, compensation and benefit plans; (iii) the effect on the Company’s competitive position within its market area of the increasing consolidation within the banking and financial services industries, including the increased competition from larger regional and out-of-state banking organizations as well as non- bank providers of various financial services; (iv) the effect of changes in interest rates; (v) the effects of health emergencies, including the spread of infectious diseases or pandemics; or (vi) the effect of changes in the business cycle and downturns in the local, regional or national economies. For a list of other factors which could affect the Company’s results, see the Company’s filings with the Securities and Exchange Commission, including “Item 1A. Risk Factors,” set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.

You should not place undue reliance on any forward-looking statements. These statements speak only as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release.

Previous press releases and additional information can be obtained from the Company’s website at www.pwod.com. 

CAMPBELL, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, and Alchip Technologies, Ltd., a top-tier ASIC leader, today announced a collaboration to enhance the delivery of high-performance SoCs with unmatched bandwidth and ease of physical design. This collaboration can deliver highly optimized SoCs across various market segments.

Arteris’ industry-leading interconnect IP solutions, renowned for their efficiency, scalability and configurability, seamlessly integrate with Alchip’s advanced semiconductor design and manufacturing platform. Their complementary expertise enhances ASIC capabilities to enable the integration of advanced technologies as physical design and performance become more challenging.

Alchip provides high-performance ASICs noted for their consistent first-time silicon successes.

“Working with Arteris reflects our strategy to provide our customers with a robust best-in-class IP portfolio. It strengthens our ability to deliver industry-leading SoCs,” said Johnny Shen, CEO of Alchip Technologies. “We leverage their network-on-chip interconnect expertise to enhance our silicon design and manufacturing capabilities, enabling us to address the semiconductor industry’s increasingly complex demands.”

“Arteris is pleased to collaborate with Alchip, a recognized leader in ASIC design and manufacturing,” said K. Charles Janac, president and CEO of Arteris. “Together, we can deliver highly differentiated SoC designs that leverage the full potential of our interconnect IP and SoC integration solutions. This collaboration aligns with our shared commitment to providing customers with high performance, power efficiency and better ROI so they are free to innovate.”

About Arteris

Arteris is a leading provider of system IP for the acceleration of system-on-chip (SoC) development across today’s electronic systems. Arteris network-on-chip (NoC) interconnect IP and SoC integration automation technology enable higher product performance with lower power consumption and faster time to market, delivering better SoC economics so its customers can focus on dreaming up what comes next. Learn more at arteris.com.

About Alchip

Alchip Technologies Ltd., founded in 2003 and headquartered in Taipei, Taiwan, is a leading global provider of silicon and design and production services for system companies developing complex and high-volume ASICs and SoCs. Alchip provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced, including 7nm, 6nm, 5nm and 4nm processes. Alchip has built its reputation as a high-performance ASIC leader through its advanced 2.5D/3D package services, CoWoS/chiplet design and manufacturing experience. Customers include global leaders in AI, HPC/supercomputer, mobile phones, entertainment devices, networking equipment and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661), is a TSMC certified member of Value Chain Alliance and 3DFabric™ Alliance. For more information, visit www.alchip.com.

© 2004-2023 Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at

https://www.arteris.com/trademarks

are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners.

NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Katia Schlienger, M.D., Ph.D., is stepping down from her position as Chief Medical Officer (CMO) to pursue new opportunities, effective September 30. Malte Peters, M.D., a current member of the Board of Directors of HOOKIPA, will lead HOOKIPA’s clinical activities ad interim as Senior Clinical Advisor until a CMO search is complete. During this time, Dr. Peters will remain a member of the HOOKIPA Board of Directors.

Dr. Peters is a seasoned executive with deep experience in bringing new therapies to patients. He retired from his role as Chief Research and Development Officer at MorphoSys in 2022. Prior, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz in Germany and spent 12 years in leadership positions at Novartis Oncology. He was responsible for multiple development programs and clinical trials at Novartis, contributing to the approval of 28 cancer therapies. He is board certified in internal medicine and earned his medical degree from Freie Universität in Berlin, with a postdoctoral fellowship in Toronto. 

“We welcome Malte to HOOKIPA as we remain laser focused on executing against our clinical priorities: to prepare for the randomized trial of HB-200 in combination with pembrolizumab, to progress our HB-300 prostate cancer program, and to advance our partnered programs in our collaborations with Roche and Gilead,” said Joern Aldag, Chief Executive Officer. “I would like to thank Katia for her many contributions to HOOKIPA, especially guiding our clinical programs and bringing our lead HB-200 program to a successful proof-of concept in Phase 2. We wish her the very best in her future endeavors.”

About HOOKIPA

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

Forward Looking Statements

Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from public health crises, the impact of public health crises on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended June 30, 2023, which is available on the SEC’s website at www.sec.gov and HOOKIPA’s website at www.hookipapharma.com.

Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/), SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our members and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the U.S. social media channels listed on our investor relations website.

For further information, please contact:

FLORHAM PARK, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) — Conduent Incorporated (Nasdaq: CNDT), a global technology-led business solutions and services company, released new research that provides a focused, in-depth view of the state of the customer experience (CX) within the retail/eCommerce vertical. At the center of the research findings, the lynchpin to standout customer experiences is a strong dedication and discipline to CX fundamentals, such as people, training, and robust processes, that layer in advanced technology, and not vice versa. The research, Experience & Loyalty Insights: A Research-Based Review, is a collaboration between Conduent and Execs In The Know.

Key Research Findings from Corporate CX Practitioners

Based on this survey of corporate CX practitioners, the research identified four areas where Retail/eCommerce brands should invest to heighten customer experience:

• Self-service capabilities for consumers to achieve quick, efficient resolution of high-volume inquiries
• Measurement of customer satisfaction and engagement as an indicator of loyalty
• A consistent, empathetic omnichannel customer experience across delivery channels (i.e., email, chat, live, social, etc.)
• Standardization of business processes leveraging journey mapping, human-centered design, and industry best practices (e.g., COPC Inc. certification across delivery centers and geographies)

CX Impacts Business

Research shows companies have made progress on the level of customer care provided, but brands still must do better. Customers are seeking out faster, simpler transactions, more consistency across channels, and easier access to live support. For example, 42% of survey respondents said the care provided today is “Better” or “Much Better” than that of three years ago. The good news for Retail/e-Commerce brands is that 62% of their customers think their customer care needs and expectations are generally being met, versus 35% of consumers across all industries.

“Regardless of the industry, companies must understand that delivering exceptional customer experience is essential to developing and maintaining loyal customers and to converting new customers. A key insight from the research is that success starts with the fundamentals of customer service, and the importance of focusing on a strategic roadmap to meet the needs of each consumer rather than the appeal of new technologies,” said Ryan Collins, Vice President of CXM at Conduent. “At the core of excellent customer experience is the focus on people, process and strategic technology, leveraged together to meet expectations today and tomorrow.”

Brands Need to Take Action

The research also identified several specific areas where brands can improve their customer care offering. These included improving access to live support, faster service, and better communication skills among agents and brand representatives with the following:

• Advanced Technology: Conduent’s cloud-based technology stack is built on a fully integrated secure platform incorporating conversational AI, sentiment analysis and predictive engagement to improve business outcomes and increase efficiency. Customers can quickly route through automated help, and workforce planning helps brands plan for peaks and valleys in support needs.
• People: Industry analysts frequently recognize Conduent for resourcing and training quality multi-skilled and multilingual talent who are empowered to empathetically work with customers to address their needs and help strengthen their relationship with brands.
• Processes: Conduent helps businesses and agencies elevate their performance by leveraging AI and analytics to automate processes and repetitive tasks, as well as develop insights to improve the customer experience.

By focusing on consumer loyalty, providing meaningful relationships, and aligning staffing, training, and processes with the brand’s cultural identity, customer experience leaders can elevate their business success.

Conduent is a strategic advisor and partner to a broad base of Fortune 100 and government clients with its industry leading customer experience solutions.

About Conduent

Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum — creating exceptional outcomes for its clients and the millions of people who count on them. The company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 60,000 associates, process expertise and advanced technologies, Conduent solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways, including delivering 43% of nutrition assistance payments in the U.S., enabling 1.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 12 million tolling transactions every day. Learn more at www.conduent.com.

Media Contact:

Lisa Patterson, Conduent, +1-816-305-4421, [email protected]

Investor Relations Contacts:

Giles Goodburn, Conduent, +1-203-216-3546, [email protected]

Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, will be presenting at the 13^th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023 at the HUNGEXPO Exhibition Centre in Budapest, Hungary.

Professor O’Sullivan’s presentation, titled, “Effects of the FABP5 Inhibitor, ART26.12, in Oxaliplatin-Induced Peripheral Neuropathy in Rats,” is scheduled for 6:30 a.m. ET / 12:30 p.m. CEST on Wednesday, September 20, 2023.

The Company recently announced that it has completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration regarding the manufacturing, preclinical and clinical development of ART26.12. Artelo plans to file an IND application for the use of ART26.12 in neuropathic pain in the first half of 2024.

To register for the event, please visit: 13th Congress of the European Pain Federation.

About ART26.12

Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a selective inhibitor of FABP5. While developing our lead molecule for chemotherapy-induced peripheral neuropathy, additional compounds from our extensive library of potent and selective inhibitors of FABPs have been identified and selected for advancement towards regulatory-enabling studies in cancer and other areas of high-unmet need where inhibition of FABPs show significant promise.

About Painful Neuropathies

Peripheral neuropathy refers to a condition in which there is damage to the peripheral nerves. These nerves are responsible for transmitting signals between the central nervous system and the rest of the body. Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often painfully debilitating complication of cancer therapies, sometimes resulting in reduction or cessation of treatment. No currently approved treatment exists for CIPN. Diabetic neuropathy refers to a type of nerve damage that occurs as a complication of diabetes. It is caused by long-term high blood sugar levels, which can lead to damage of the blood vessels and nerves throughout the body. The prevalence of diabetic neuropathy is significant due to the increasing number of people with diabetes worldwide.

About Artelo Biosciences

Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development

LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) — IMUNON,
Inc.
(Nasdaq:
IMNN)
, a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14^th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in the Scientific Presentations section of IMUNON’s website or here. Following management’s presentations, a Q&A session will be available via the chat function of the webcast.

The Event’s Speakers

IMUNON presenters include:

• Dr. Corinne Le Goff, President and Chief Executive Officer
• Khursheed Anwer, Ph.D., Executive Vice President and Chief Science Officer

Guest key opinion leader presenters include:

• Sallie Permar, M.D., Ph.D., Chair of the Department of Pediatrics at Weill Cornell Medicine and Pediatrician-in-Chief at New York-Presbyterian/Weill Cornell Medical Center and New York-Presbyterian Komansky Children’s Hospital. She is also Nancy C. Paduano Professor and Chair, Weill Cornell Medicine.
• Patrick Ott, M.D., Ph.D., Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. He is also an attending physician in the Department of Medicine at Brigham and Women’s Hospital and is an Associate Professor at Harvard Medical School.

About IMUNON

IMUNON is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas^TM, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine ^TM is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The third modality, FixPlas ^TM, concerns the application of our DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, which is in the discovery phase, IndiPlas ^TM, will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting IND-enabling preclinical studies for the development of a COVID-19 booster vaccine: IMNN-101. The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma: IMNN-201. We will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information on IMUNON, visit www.imunon.com.

Contacts:

# # #